New pill targets 'Undruggable' KRAS cancer mutations in first human trial

NCT ID NCT07094113

Recruiting now Disease control Sponsor: Amgen Source: ClinicalTrials.gov ↗

Summary

This early-stage study is testing a new oral drug called AMG 410, alone or with other treatments, for people with advanced solid tumors that have KRAS gene changes. The main goals are to find the safest and most effective dose and to see how the body processes the drug. Researchers will enroll about 434 adults who have run out of standard treatment options to see if AMG 410 can help control their cancer.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for KRAS ALTERED ADVANCED OR METASTATIC SOLID TUMORS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Aichi Cancer Center
RECRUITING

Nagoya, Aichi-ken, 464-8681, Japan
Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda
RECRUITING

Milan, 20162, Italy
Centre Leon Berard
RECRUITING

Lyon, 69008, France
Centro Ricerche Cliniche Di Verona Societa responsabilita limitata
RECRUITING

Verona, 37134, Italy
Chris OBrien Lifehouse
RECRUITING

Camperdown, New South Wales, 2050, Australia
City of Hope National Medical Center
RECRUITING

Duarte, California, 91010, United States
Duke Cancer Center
RECRUITING

Durham, North Carolina, 27710, United States
Emory University
RECRUITING

Atlanta, Georgia, 30322, United States
Fundacion Jimenez Diaz
RECRUITING

Madrid, 28040, Spain
Gustave Roussy
RECRUITING

Villejuif, 94805, France
Massachusetts General Hospital
RECRUITING

Boston, Massachusetts, 02114, United States
National Cancer Center Hospital
RECRUITING

Chuo-ku, Tokyo, 104-0045, Japan
National Cancer Center Hospital East
RECRUITING

Kashiwa-shi, Chiba, 277-8577, Japan
Next Oncology
RECRUITING

San Antonio, Texas, 78229, United States
Next Virginia
RECRUITING

Fairfax, Virginia, 22031, United States
Peter MacCallum Cancer Centre
RECRUITING

Parkville, Victoria, 3050, Australia
Princess Margaret Cancer Centre
RECRUITING

Toronto, Ontario, M5G 1Z5, Canada
Rigshospitalet
RECRUITING

Copenhagen, 2100, Denmark
Royal Marsden Hospital
RECRUITING

Sutton, SM2 5PT, United Kingdom
Sarah Cannon Research Institute Oncology Partners
RECRUITING

Nashville, Tennessee, 37203, United States
Sir Mortimer B Davis - Jewish General Hospital
RECRUITING

Montreal, Quebec, H3T 1E2, Canada
Siteman Cancer Center - Washington University
RECRUITING

St Louis, Missouri, 63110, United States
The Queen Elizabeth Hospital
RECRUITING

Woodville South, South Australia, 5011, Australia
Thomas Jefferson University
RECRUITING

Philadelphia, Pennsylvania, 19107, United States
Universitaetsklinikum Essen
RECRUITING

Essen, 45147, Germany
Universitair Medisch Centrum Utrecht
RECRUITING

Utrecht, 3584 CX, Netherlands
Universitair Ziekenhuis Gent
RECRUITING

Ghent, 9000, Belgium

Conditions

Explore the condition pages connected to this study.

KRAS ALTERED ADVANCED OR METASTATIC SOLID TUMORS